Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on August 27, 2020, reporting events occurring on August 26, 2020. The company is listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
On August 26, 2020, the Company announced an increase to the size of its previously announced registered public offering of common stock. This offering is being conducted pursuant to an Underwriting Agreement with H.C. Wainwright & Co., LLC.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) for details on the offering but does not include specific management commentary, forward-looking guidance, risk factors, or contingencies within the body of this 8-K text.
Investor Verification Checklist
- Verify the specific number of shares and total proceeds from the increased offering size by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the final terms of the Underwriting Agreement with H.C. Wainwright & Co., LLC.
- Check subsequent filings for the closing date and actual capital raised from this offering.